Corporate News
LR Health & Beauty strengthens its management team with Martin Lipp as new Chief Financial Officer (CFO)
Ahlen, 7 September 2026 – The LR Health & Beauty GmbH, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, is strengthening its management team: effective 7 September 2026, Martin Lipp takes over as Chief Financial Officer (CFO) and joins the Executive Management Team. In his new role, Martin Lipp will be responsible for Global Controlling & Finance, Legal, IT and Operations.
“With Martin Lipp, we are gaining a highly experienced international finance executive with extensive expertise in managing and transforming businesses. During the current transition phase, he will enrich the senior management in particular with his strong transformation expertise and excellent know-how in the areas of finance, operations and IT. Together, we will consistently drive forward the implementation of our strategy with a clear focus on profitability, efficiency and sustainable growth,” says Jörg Körfer, CEO of the LR Group.
Martin Lipp brings around 20 years of leadership experience in international companies across three continents. Throughout his career, he has led finance organisations in the healthcare, consumer goods, automotive and renewable energy sectors. Most recently, he served as CFO of the Brazilian Correias Mercúrio Group. Prior to this, as CFO of the Schletter Solar Group, an international provider of solar mounting systems, he successfully guided the company through a period of restructuring and transformation and supported its subsequent change of ownership. He has also held senior finance positions at McKesson and Benteler Automotive.
“I am very much looking forward to my new role at LR and the trust placed in me. The company has a strong brand and an attractive business model, which I see as offering significant potential. Together with the management team and our employees, I want to contribute to returning the LR Group to a path of sustainable and profitable growth,” says Martin Lipp, new CFO of the LR Group.
LR Group
Operating under the guiding principle “More quality for your life”, the LR Group, headquartered in Ahlen, Westphalia, successfully produces and distributes a range of high-quality nutritional supplements and cosmetics in 32 countries. As an attractive social commerce company, LR supports personal interaction within its community with efficient digital solutions.
Since 1985, LR has been firmly established in the market as a “people business”, where people and personal advice take centre stage. In an era of changing working environments, the business model particularly appeals to those seeking greater flexibility, a better work–life balance and increased financial independence.
Processing Aloe Vera has been one of LR’s core competencies for over 20 years. Only the valuable inner leaf is used for its products. In Ahlen, the company has built one of Europe’s most modern Aloe Vera production facilities for Aloe Vera drinking gels.
In autumn 2009, LR founded the LR Global Kids Fund e.V., which works with local institutions to provide efficient, unbureaucratic support for disadvantaged children and their families in many countries around the world. For further information on our commitment to sustainability, please see our Sustainability Report.
Contact:
Public Relations:
LR Global Holding
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone.: 02382 7658-106
E-Mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Friedrichstraße 22
65185 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
LR Health & Beauty SE publishes figures for the first half of 2026
- H1 2026 sales reached EUR 118.6 million, with normalized EBITDA of EUR 8.7 million
- In the transformation year 2026, LR systematically advances strategic initiatives to position the organization for the future
- Business Days in September boost international partner community activities
Ahlen, 24 August 2026 – LR Health & Beauty SE, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, has today published its figures for the second quarter and first half of 2026.
In the second quarter of the 2026 financial year, LR Health & Beauty SE generated sales (revenue from goods sold) of EUR 57.8 million (Q2 2025: EUR 68.9 million), representing a decrease of 16.1% compared with the same period last year. For the first half of the year, sales amounted to EUR 118.6 million, which was 17.0% lower than the previous year’s level of EUR 142.9 million. Sales performance continued to be characterized by a challenging market environment, with consumer sentiment generally subdued.
In addition to the decrease in sales, one-off effects relating to the reorganization of the financing structure had a particularly negative impact on earnings. In the first six months of 2026, LR Health & Beauty SE generated reported EBITDA of EUR 3.9 million, which represents a decrease compared with the previous year (H1 2025: EUR 13.3 million). Normalized EBITDA amounted to EUR 8.7 million in the first six months of 2026, compared with EUR 15.3 million in the same period of the previous year.
Jörg Körfer, CEO of LR Health & Beauty SE, comments: “With the successful completion of our financial realignment, we have already made significant progress in the transformation year 2026 towards positioning LR for the future. On this basis, we are consistently driving forward our strategic initiatives, with a particular focus on developing the organization sustainably and enabling future growth at LR. At the same time, we are looking forward to the upcoming Business Days in September. They provide the ideal platform to further deepen our dialogue with our partner community, jointly advance our activities and provide important impetus for LR’s future.”
As part of its strategic initiatives, LR is implementing targeted measures in key areas that are crucial to the company’s future. These include investments in production at the Ahlen site, the optimization of logistics processes and support for international growth. An important element of these initiatives is the expansion of in-house production, which will enable LR to further strengthen its own value creation and provide additional flexibility to scale the business. To this end, LR is also driving forward the digitalization and automation of internal processes.
The full report for the second quarter and the first six months of 2026 is available online from today on the company’s website at https://ir.lrworld.com/.
LR Group
Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.
In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.
Contact:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
IR Contact:
cometis AG
Thorben Burbach
Friedrichstraße 22
65185 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
LR Health & Beauty SE publishes final 2025 annual report and continues to execute its strategic initiatives
- Preliminary FY 2025 sales and EBITDA confirmed
- Solid financial footing provides scope to consistently advance strategic initiatives aimed at optimizing production, logistics and sales
Ahlen, 4 August 2026 – LR Health & Beauty SE, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, has today published its final annual report for 2025.
The sales and earnings figures for the 2025 financial year, as communicated in the preliminary results, are thereby confirmed: for the full 2025 year, the LR Group generated sales (revenue from goods sold) of EUR 277.1 million (2024: EUR 289.2 million). Meanwhile, one-off effects arising from the reorganization of the financing structure weighed on earnings performance. For the full 2025 year, this resulted in reported EBITDA of EUR 16.5 million, compared with EUR 27.3 million in the previous year. Normalized EBITDA for the year amounted to EUR 22.5 million (2024: EUR 32.6 million).
Jörg Körfer, CEO of LR Health & Beauty SE, comments: “The 2026 financial year is a transitional year for LR, during which we have laid the groundwork – both financially and strategically – for sustainable business growth and performance. The newly established financing structure gives us the momentum we need to continue to consistently pursue the initiatives we have launched in production, logistics and sales in the second half of the year. In this context, we are committed to working closely with our partners and are continuing to expand these relationships internationally.”
Expanding in-house production is a key strategic pillar. As part of its strategic measures, LR is investing over 2 million euros in a new, high-performance production line, thereby centralizing the manufacture of the 5in1 product category entirely at its site in Ahlen in the future. This includes the established products LR 5in1 Beauty Elixir and LR 5in1 Men’s Shot. The new production facility is designed to have an annual capacity of up to 40 million units and also paves the way for further product innovations in the area of modern nutritional supplement concepts.
The full 2025 Annual Report is available from today on the company’s website at https://ir.lrworld.com.
LR Group
Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.
In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.
Contact:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
IR Contact:
cometis AG
Thorben Burbach
Friedrichstraße 22
65185 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
Ad-hoc Announcements
LR HEALTH & BEAUTY SE INITIATES A WRITTEN PROCEDURE UNDER ITS OUTSTANDING BOND LOAN IN RESPECT OF TEMPORARY WAIVERS AND SUPER SENIOR BRIDGE FINANCING
Ad-hoc Announcements - LR Health & Beauty SE | 2026-03-06 | 16:31 CET/CEST
Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR HEALTH & BEAUTY SE INITIATES A WRITTEN PROCEDURE UNDER ITS OUTSTANDING BOND LOAN IN RESPECT OF TEMPORARY WAIVERS AND SUPER SENIOR BRIDGE FINANCING
Ahlen, 6 March 2026 – LR Health & Beauty SE (the “Company”) has, as of today, entered into further agreements with holders of the Company’s 2024/2028 bonds (ISIN: NO0013149658) (the “Bondholders” and the “Bonds”) representing more than two thirds (2/3) of the nominal amount of the Bonds (the “Majority Bondholders”) and the Company's shareholder regarding a comprehensive restructuring of the Bonds and the Company’s capital structure (the “Restructuring”).
A comprehensive restructuring, such as the Restructuring, will take time to implement which means that the Company will be in need of bridge financing in an amount of EUR 10,000,000 until the Restructuring is implemented. Certain Bondholders have undertaken to provide a bridge financing in the amount of EUR 10,000,000, having a super senior ranking in relation to the Bonds (the "Super Senior Bridge Financing"). The Super Senior Bridge Financing is intended to be refinanced in connection with closing of the Restructuring. Such Super Senior Bridge Financing may or may not share the security and guarantee package of the Bonds under an intercreditor agreement (in part or in full) and may further benefit from certain Super Senior Bridge Financing only share security.
In addition, the Majority Bondholders agreed to further extend the standstill undertaking comprising, inter alia, that Bondholders shall not derive any rights from breaches of the maintenance test (including the leverage covenant) or from any non-payments of interest until end of June 2026 (subject to extension).
In light of the above, the Company has today initiated a written procedure (the “Written Procedure”) under the Bonds to implement the above by way of amendments to and temporary waivers under the terms and conditions for the Bonds.
The notice of the Written Procedure and further details are accessible on the Company’s website at https://ir.lrworld.com/en/bond/.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
End of inside information
LR HEALTH & BEAUTY SE REACHES AN AGREEMENT WITH BONDHOLDERS AND SHAREHOLDER REGARDING A COMPREHENSIVE RESTRUCTURING OF THE 2024/2028 BOND – EUR 20 MILLION IN NEW CAPITAL AND SIGNIFICANTLY REDUCED DEBT STRUCTURE
Ad-hoc Announcements - LR Health & Beauty SE | 2026-02-11 | 19:50 CET/CEST
Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR HEALTH & BEAUTY SE REACHES AN AGREEMENT WITH BONDHOLDERS AND SHAREHOLDER REGARDING A COMPREHENSIVE RESTRUCTURING OF THE 2024/2028 BOND – EUR 20 MILLION IN NEW CAPITAL AND SIGNIFICANTLY REDUCED DEBT STRUCTURE
Ahlen, 11 February 2026 – Today, LR Health & Beauty SE (the “Company”) reached an agreement with bondholders representing more than two thirds (2/3) of the nominal amount of the Company’s outstanding 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”) as well as the Company’s shareholder regarding a comprehensive restructuring of the Bonds and the Company’s capital structure.
The restructuring comprises an aggregate equity and debt injection of EUR 20 million in new capital, consisting of a (i) EUR 10 million equity contribution and (ii) EUR 10 million in New Money Senior Bonds (as defined below). The shareholder Evoco will continue its commitment to the Company demonstrating confidence and support to the Company.
The Company’s debt structure will be significantly downsized and restructured as follows:
- Senior secured debt of EUR 62.5 million comprising of the following tranches which will rank pari passu with each other and carry a fixed cash interest of 6.75% per annum:
- EUR 10 million new money senior bonds (the “New Money Senior Bonds”), to be subscribed for in cash by bondholders (offered pro rata to all bondholders). The New Money Senior Bond issue will be fully backstopped by certain major bondholders.
- EUR 20 million reinstated elevated bonds (the “Reinstated Elevated Bonds”), allocated pro rata to bondholders who participate in the New Money Senior Bonds.
- EUR 32.5 million reinstated bonds (the “Reinstated Bonds”), allocated pro rata to all existing bondholders.
- Unsecured subordinated junior bonds of EUR 27.5 million (the “Junior Bonds”), allocated pro rata to all existing bondholders, with payment-in-kind interest stepping up linearly from 6% per annum year one to 10% per annum year five, maturing in 2031.
- The part of the nominal amount of the Bonds (including accrued interest thereunder) that is not reinstated into Reinstated Elevated Bonds, Reinstated Bonds or Junior Bonds shall be written off in its entirety.
The agreement is set out in a lock-up agreement entered into between the Company, its shareholder and bondholders representing more than two thirds (2/3) of the nominal amount for the Bonds, whereunder inter alia the parties have undertaken to implement the comprehensive restructuring and the bondholders have agreed to not accelerate the Bonds during the lock-up period (ending 30 April 2026). Implementation of the restructuring is subject to approval by bondholders in one or several written procedures and by formal shareholder approval, and shall be completed by the end of the lock-up period.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
End of inside information
LR HEALTH & BEAUTY SE: PRELIMINARY RESULTS FOR FINANCIAL YEAR 2025 / TARGETED EQUITY CONTRIBUTION / TARGETED RESTRUCTURING OF THE 2024/2028 BONDS
Ad-hoc Announcements - LR Health & Beauty SE | 2026-01-23 | 21:21 CET/CEST
Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR HEALTH & BEAUTY SE: PRELIMINARY RESULTS FOR FINANCIAL YEAR 2025 / TARGETED EQUITY CONTRIBUTION / TARGETED RESTRUCTURING OF THE 2024/2028 BONDS
Ahlen, 23 January 2026 – Today, based on the preliminary financial results for the financial year 2025, the Management Board of LR Health & Beauty SE (the “Company”) expects an EBITDA* reported of around EUR 16 million for the financial year 2025 (previously expected to be between EUR 17.0 million and EUR 20.0 million). At the same time, the Management Board of the Company expects sales (revenue from goods sold) of around EUR 277 million for the full year 2025 (previously expected to be between EUR 276 million and EUR 281 million).
Also today, EY-Parthenon announced the completion of a draft IDW S 6 restructuring opinion in respect of the Company. Pursuant to the analysis set out in that draft restructuring opinion, the Company will for the financial year 2028 achieve an EBITDA* of EUR 27.3 million and sales of EUR 281.5 million in the sensitivity case, and an EBITDA* of EUR 31.4 million as well as sales of EUR 284.7 million in the management case.
Against this background, the Company decided today to enter into discussions with its shareholder and with the bondholders of the Company’s outstanding 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”). The aim of such discussions is to explore the possibility of a financial restructuring of the Company comprising (the following measures together the “Restructuring Measures”):
- an equity contribution from the Company’s shareholder in the amount of EUR 10 million for financing of the Company’s operating business; and
- bondholder approval of certain amendments to the terms and conditions of the Bonds (through a new written procedure under the Bonds) in respect of:
- a write-down of 55 % of the nominal amount of the Bonds on a pro rata basis (including the capitalised interest in respect of the interest payments under the Bonds due in November 2025 and February 2026), after which the outstanding nominal amount under the Bonds will amount to EUR 61.3 million;
- an extension of the term of the Bonds until 31 December 2029;
- a deferral of the interest payments under the Bonds due in November 2025 and February 2026 (on a capitalising basis and subject to write-down mechanism set out above) and other interest payments under the Bonds due during the period up to and including May 2027 (on a capitalising basis) until the Bonds’ extended maturity date;
- cash sweep mechanisms for excess cash over a EUR 15 million threshold; and
- a contractual right (Besserungsschein) for the bondholders to receive cash in an aggregate amount of up to EUR 74.9 million (being equal to the written down amount) out of any excess cash received out of a refinancing of the Bonds.
The holders of the Bonds shall be entitled to participate in the refinancing process.
If the Restructuring Measures cannot be implemented, it is currently assumed that the holders of the Bond could expect an insolvency quota of around 6% in an insolvency liquidation scenario.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
*EBITDA, based on IFRS as used in the unaudited consolidated interim report of the Company for Q3 2025 which can be found on the Company’s website at https://media.lrworld.com/IR/Interim_Report_Q3_2025.pdf.
End of inside information
Directors‘ Dealings
At the moment no news are available.